Chime Financial Confirms Strong 2025 Performance with Audited Results, Reports Positive Adjusted EBITDA
Summary
Chime Financial's 2025 annual report confirms strong revenue and member growth, with Adjusted EBITDA turning positive. A large net loss was primarily due to IPO-related stock compensation, and the company initiated a significant share repurchase program.
Key Events
-
Full Year 2025 Revenue Growth
Revenue increased 31% year-over-year to $2.19 billion, driven by growth in active members and new product launches.
-
Adjusted EBITDA Turns Positive
The company achieved a positive Adjusted EBITDA of $126.6 million in 2025, a significant improvement from a loss in the prior year, reflecting enhanced operational performance.
-
Net Loss Driven by IPO-Related Stock Compensation
A net loss of $1.01 billion was reported, largely due to $1.09 billion in non-cash stock-based compensation expense from equity awards vesting upon the June 2025 IPO.
-
Strong Member and Purchase Volume Growth
Active members grew 19% to 9.5 million, and purchase volume increased 16% to $133.7 billion, indicating robust user engagement.
Analysis
Chime Financial's 2025 annual report confirms robust operational performance, with revenue increasing 31% to $2.19 billion and active members growing 19% to 9.5 million. A significant highlight is the shift to a positive Adjusted EBITDA of $126.6 million, indicating improved underlying profitability and operational efficiency. While the company reported a net loss of $1.01 billion, this was primarily driven by a substantial $1.09 billion in non-cash stock-based compensation expense related to the vesting of equity awards upon its June 2025 IPO. The company also initiated a $200 million share repurchase program in November 2025, having already repurchased $77.5 million by year-end, signaling management confidence. Investors should note the 85% increase in transaction and risk losses, primarily from liquidity products and isolated fraud incidents, which warrants continued monitoring.
At the time of this filing, CHYM was trading at $22.31 on NASDAQ in the Finance sector, with a market capitalization of approximately $8.7B. The 52-week trading range was $16.17 to $44.94. This filing was assessed with positive market sentiment and an importance score of 8 out of 10.